Details for Patent: 7,884,136

Title:	Modified-release formulations of a bupropion salt
Abstract:	The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
Inventor(s):	Oberegger; Werner (Mississauga, CA), Zhou; Fang (Davie, FL), Maes; Paul (Caluire et Cuire, FR), Turchetta; Stefano (Rome, IT), Jackson; Graham (Celbridge, IE), Massardo; Pietro (Roma, IT), Saleh; Mohammad Ashty (Oakville, CA)
Assignee:	Biovail Laboratories International S.R.L. (St. Michael, BB)
Filing Date:	Jun 27, 2006
Application Number:	11/993,723
Claims:	1. A composition, comprising at least one pharmaceutically acceptable excipient; and two or more of the following crystalline compounds: (i) a crystalline compound of the formula: ##STR00004## exhibiting an X-ray powder diffraction pattern with an X-ray source of Cu/30 kV and having characteristic peaks at about 6.70 .degree.2Theta, about 12.51 .degree.2Theta, about 19.60 .degree.2Theta, about 22.93 .degree.2Theta and about 26.11 .degree.2Theta; (ii) a crystalline compound of the formula: ##STR00005## exhibiting an X-ray powder diffraction pattern with an X-ray source of Cu/30 kV and having characteristic peaks at about 6.53 .degree.2Theta, about 13.03 .degree.2Theta, about 15.91 .degree.2Theta, about 16.52 .degree.2Theta and about 23.11 .degree.2Theta; and (iii) a crystalline compound of the formula: ##STR00006## exhibiting an X-ray powder diffraction pattern with an X-ray source of Cu/30 kV and having characteristic peaks at about 8.06 .degree.2Theta, about 12.28 .degree.2Theta, about 16.00 .degree.2Theta, about 18.07 .degree.2Theta and about 25.12 .degree.2Theta. 2. The composition according to claim 1, comprising three of the crystalline compounds. 3. A composition, comprising at least one pharmaceutically acceptable excipient; and two or more of the following crystalline compounds: (i) a crystalline compound of the formula: ##STR00007## exhibiting an X-ray powder diffraction pattern with an X-ray source of Cu/30 kV and having five or more characteristic peaks selected from the group consisting of about 6.70 .degree.2Theta, about 12.51 .degree.2Theta, about 13.83 .degree.2Theta, about 19.60 .degree.2Theta, about 22.93 .degree.2Theta, about 23.98 .degree.2Theta, about 24.76 .degree.2Theta, about 25.51 .degree.2Theta, about 26.11 .degree.2Theta and about 32.70 .degree.2Theta; (ii) a crystalline compound of the formula: ##STR00008## exhibiting an X-ray powder diffraction pattern with an X-ray source of Cu/30 kV and having five or more characteristic peaks selected from group consisting of about 6.53 .degree.2Theta, about 13.03 .degree.2Theta, about 15.91 .degree.2Theta, about 16.52 .degree.2Theta, about 21.95 .degree.2Theta, about 23.11 .degree.2Theta, about 25.83 .degree.2Theta, about 26.83 .degree.2Theta, about 28.81 .degree.2Theta and about 32.42 .degree.2Theta; and (iii) a crystalline compound of the formula: ##STR00009## exhibiting an X-ray powder diffraction pattern with an X-ray source of Cu/30 kV and having five or more characteristic peaks selected from the group consisting of about 8.06 .degree.2Theta, about 12.28 .degree.2Theta, about 16.00 .degree.2Theta, about 18.07 .degree.2Theta, about 19.67 .degree.2Theta, about 23.42 .degree.2Theta, about 24.24 .degree.2Theta, about 25.12 .degree.2Theta, about 28.99 .degree.2Theta and about 29.66 .degree.2Theta. 4. The composition according to claim 3, comprising three of the crystalline compounds.